IGF-I and diabetes in adolescence

Diabetes and Metabolism

Volumn 24, Issue 2, 1998, Pages 101-107

  Dunger, D B ^a   Acerini, C L ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Adolescence; Diabetes; IGF 1

Indexed keywords

GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; GROWTH HORMONE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PUBERTY; RECOMBINANT PROTEINS;

EID: 0031841326     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
2. The DCCT Research Group. The absence of a glycaemic threshold for the development of long-term complications : the perspective of the Diabetes Control and Complications Trial. Diabetes, 1996, 45, 1289-1298.
3. Mann NP, Johnston DI. Total glycated haemoglobin (HbA1) levels in diabetic children. Arch Dis Child, 1982, 57, 434-437.
4. Rogers GD, White B, Shalwitz RA, Palmberg P, Smith ME, Santiago JV. The effect of puberty on the development of early diabetic microvascular disease in insulin-dependent diabetes. Diabetes Res Clin Pract, 1987, 3, 39-44.
5. The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus : Diabetes Control and Complications Trial. J Pediatr, 1994, 125, 177-188.
6. Edge JA, Dunger DB, Matthews DR, Gilbert JR, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab, 1990, 71, 1356-62.
7. Batch JA, Werther GA. Changes in growth hormone concentration during puberty in adolescents with insulin-dependent diabetes. Clin Endocrinol, 1992, 36, 411-416.
8. Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, Sherwin RS. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med, 1981, 305, 303-307.
9. Amiel SA, Sherwin RS, Hintz RL, Gertner JM, Press M, Tamborlane WV. Effects of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes, 1984, 33, 1175-1179.
10. Taylor AM, Dunger DB, Grant DB, Preece MA. Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin-dependent diabetes mellitus compared with puberty-matched controls. Diabetes Res, 1988, 9, 177-181.
11. Batch JA, Baxter RC, Werther G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab, 1991, 73, 964-968.
12. Clayton KL, Holly JMP, Carlsson LMS, et al. Loss of the normal relationships between growth hormone, growth hormone binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf). 1994, 41, 517-524.
13. Holl RW, Seigler B, Scherbaum WA, Heinze E. The serum growth hormone-binding protein is reduced in young patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1993, 76, 165-167.
14. Massa G, Dooms L, Bouillon R, Vanderschureren-Lodeweyckx M. Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type I (insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 239-243.
15. Baxter RC, Turtle JR. Regulation of hepatic growth hormone receptors by insulin. Biochem Biophys Res Comm, 1978, 84, 350-357.
16. Maes M, Underwood LE, Ketelslegers J-M. Low serum somatomedin-C in insulin-dependent diabetes : evidence for a post-receptor mechanism. Endocrinology, 1986, 118, 377-382.
17. Arslanian SA, Menon RK, Gierl AP, Heil BV, Foley Jr TP. Insulin therapy increases low plasma growth hormone binding protein in children with new onset type I diabetes. Diabetic Med, 1993, 10, 833-838.
18. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-I (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab, 1994, 79, 872-878.
19. Wurzburger MI, Prevelic GM, Sonksen PH, Balint-Peric LA, Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab, 1993, 77, 267-272.
20. Shisko PI, Kovaler PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes, 1992, 41, 1042-1049.
21. Taylor AM, Dunger DB, Preece MA, et al. The growth hormone independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetes. Clin Endocrinol (Oxf), 1990, 32, 229-239.
22. Bereket A, Lang C, Blethen S, Co Ng L, Wilson T. Insulin treatment normalizes reduced free Insulin-like growth factor-I concentrations in diabetic children. Clin Endocrinol, 1996, 45, 321-326.
23. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents and adults : relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab, 1994, 78, 744-752.
24. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz R. Somatomedin C mediates growth hormone negative feed-back by the effects on both the hypothalamus and the pituitary. Science, 1981, 212, 1279-1281.
25. Brazeau P, Guillemin R, Ling N, van Wyk J, Humbel R. Somatomedin inhibition of the growth hormone secretion stimulated by the hypothalamic factor somatocrinin or the synthetic peptide hpGRF. CR Seances Acad Sci III, 1982, 295, 651-654.
26. Ceda GP, Davis RG, Rosenfeld RG, Hoffman AR. The growth hormone (GH)-releasing hormone (GHRH)-GH somatomedin axis : evidence of rapid inhibition of GHRH elevated GH release by insulin-like growth factors I and II. Endocrinology, 1987, 120, 1658-1662.
27. Ismail IS, Scanlon MF, Peters JR. Cholinergic control of growth hormone (GH) responses to GH releasing hormone in insulin-dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback. Clin Endocrinol, 1993,38, 149-157.
28. Cohen RM, Abplanalp WA. Resistance of growth hormone secretion to somatostatin in men with type I diabetes mellitus. Diabetes, 1991, 40, 1251-1258.
29. Ismail IS, Scanlon MF, Peters JR, Effects of ambient glycaemic state on growth hormone responsiveness in insulin-dependent diabetes. Clin Endocrinol, 1991, 35, 499-504.
30. Pal BR, Matthews DR, Edge JA, Mullis PE, Hindmarsh PC, Dunger DB. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin-dependent diabetes mellitus and are unaffected by short-term euglycaemia. Clin Endocrinol, 1993, 38, 93-100.
31. Bratusch-Marrain PR, Smith D, DeFronzo RA. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab, 1982, 55, 973-982.
32. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes, 1982, 31, 663-669.
33. Fowelin J, Attoal S, Van Schenck H, Smith U, Lager I. Characterisation of the insulin-dependent effect of growth hormone in man. Diabetologia, 1991, 34, 500-6.
34. Pal BR, Philips PE, Matthews DR, Dunger DB. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with insulin-dependent diabetes mellitus. Diabetologia, 1992, 35, 542-549.
35. Edge JA, Matthews DR, Dunger DB. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol, 1990 ; 33 : 729-37.
36. Perriello G, Defeo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type I (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahapatic) sensitivity to insulin in the absence of insulin waning. Diabetologia, 1990, 33, 52-59.
37. Beaufrere B, Beylot M, Metz C, et al. Dawn phenomenon in Type I (insulin-dependent) diabetic adolescents: Influence of nocturnal growth hormone secretion. Diabetologia, 1988, 31, 607-611.
38. Amiel SA, Sherwin RS, Simonson DV, Laumtano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycaemic control in adolescents with diabetes. N Engl J Med, 1986, 315, 215-219.
39. Edge JA, Matthews DR, Dunger DB. Failure of current insulin regimes to meet the overnight requirements of adolescents with insulin-dependent diabetes. Diabetes Res, 1990, 15, 109-112.
40. Edge JA, Pal BR, Harris DA, Matthews DR, Phillips PE, Dunger DB. Evidence for a role for insulin and growth hormone in the overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents. Diabetes Care, 1993, 16, 1011-1018.
41. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor binding protein-I modulates blood glucose levels. Endocrinology, 1991, 129, 2254-2256.
42. Cotterill AM, Daly F, Holly JMP, et al. The 'dawn phenomenon' in adolescents with insulin-dependent diabetes mellitus : Possible contribution of insulin-like growth binding protein-I. Clin Endocrinol, 1995, 43, 567-574.
43. Salardi S, Cacciari E, Ballardini D, et al. Relationships between growth factors (somatomedin-C and growth hormone) and body development, metabolic control and retinal changes in children and adolescents with IDDM. Diabetes, 1986, 35, 832-836.
44. Brown M, Ahmed ML, Clayton K, Dunger DB. Growth during childhood and final height in type I diabetes mellitus. Diabetic Med, 1994, 11, 182-187.
45. Du Caju MVL, Rooman RP, Op De Beeck L. Longitudinal data on growth and final height in diabetic children. Pediatr Res, 1995, 38, 607-611.
46. Jos J, Meteyer I, Farkas D, Oberkampf B. Growth of children with insulin-dependent diabetes. Study of 104 cases. Arch Pediatr, 1996, 3, 218-226.
47. Strasser-Vogel B, Blum W, Past R, et al. Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins -1, -2 and -3 in children and adolescents with diabetes mellitus Correlation with metabolic control and height attainment. J Clin Endocrinol Metab, 1995, 80, 1207-1213.
48. Merimee TJ, Russell B, Quinn S, Riley W. Hormone and receptor studies : relationship to linear growth in childhood and puberty. J Clin Endocrinol Metab, 1991, 73, 1031-1037.
49. Thon A, Heinze E, Feilen KD, et al. Development of height and weight in children with diabetes mellitus : report on two prospective multicentre studies, one cross-sectional, one longitudinal. Eur J Pediatr, 1992, 151, 258-262.
50. Adcock CJ, Perry LA, Lindsell DRM, et al. Menstrual irregularities are more common in adolescents with type I diabetes : association with poor glycaemic control and weight gain. Diabetic Med, 1994, 11, 465-470.
51. Burger W, Hovener, Dusterhus R, Hartmann R, Wever B. Prevalence and development of retinopathy in children and adolescents with type I (insulin-dependent) diabetes mellitus. A longitudinal study. Diabetologia, 1986, 29, 17-22.
52. Kernell A, Dedorsson I, Johansson B, et al. Prevalence of diabetic retinopathy in children and adolescents with IDDM. Diabetologia, 1997, 40, 307-310.
53. Gerich JE. Role of growth hormone in diabetes mellitus. N Engl J Med, 1984, 310, 848-850.
54. Dills DG, Moss SE, Klein R, Klein BEK, Davis M. Is insulin-like growth factor I associated with diabetic retinopathy? Diabetes, 1990, 39, 191-195.
55. Wang Q, Dills DG, Klein R, Klein BEK, Moss SE. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy ? Diabetes, 1995, 44, 161-164.
56. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina : comparative studies with basic fibroblast growth factor. Diabetologia, 1993, 36, 282-291.
57. Merimee TJ, Zapf J, Froesch R. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med, 1983, 309, 527-530.
58. Wilton P, Sietnieks A, Gunnarsson R, Berger L, Grahnen A. Pharmacokinetic profile of recombinant human insulin-like growth factor I given subcutaneously in normal subjects. Acta Paed, 1991, Suppl 377, 111-114.
59. Cheetham TD, Taylor AM, Holly JMP, Clayton K, Cwyfan-Hughes S, Dunger DB. The effects of recombinant human insulin-like growth factor-I (rhIGF-I) adminstration on the levels of IGF-I, IGF-II and IGF binding proteins in adolescents with insulin-dependent diabetes mellitus. J Endocrinol, 1994, 142, 367-374.
60. Cheetham TD, Clayton KL, Taylor AM, Holly JMP, Matthew DR, Dunger DB. The effects of recombinant human insulin-like growth factor I (rhIGF-I) on growth hormone secretion in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf), 1994, 40, 515-522.
61. Cheetham TD, Jones J, Taylor AM, Holly JMP, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 678-681.
62. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1994, 79, 1040-1045.
63. Cheetham TD, Connors M, Clayton K, Watts A, Dunger DB. Insulin sensitivity before and after recombinant human insulin-like growth factor I (rhIGF-I) administration in adolescents with IDDM : importance of GH concentrations. Clin Endocrinol, 1997, 46, 415-425.
64. Crowne EC, Samra JS, Cheetham T, Watts A, Holly JMP, Dunger DB. Recombinant human IGF-I abolishes changes in insulin requirements consequent upon growth hormone (GH) pulsatility in young adults with Type I diabetes mellitus. Metabolism, 1998, 47, 31-38.
65. Hussain MA, Scmitz O, Mengel A, et al. Insulin-like growth factor I stimultes lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest, 1993, 92, 2249-2256.
66. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract, 1995, 28, S185-194.
67. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes, 1996, 45, 91-100.
68. Sherwin RS, Borg WP, Boulware SD. Metabolic effects of insulin-like growth factor I in normal humans. Horm Res, 1994, 41, 97-102.
69. Cheetham TD, Holly JMP, Clayton K, Curfan-Hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor-I administration in adolescents with type I diabetes. Diabetic Medicine, 1995, 12, 885-892.
70. Quattrin T, Thrailkill K, Baker L, et al. Dual hormonal replacement with insulin and recominant human insulin-like growth factor-I in IDDM. Effects on glycaemic control, IGF-I levels and safety profile. Diabetes Care, 1997, 20, 374-380.
71. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. A randomised placebo-controlled trial of human recombinant insulin-like growth factor-I treatment as an adjunct to intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet, 1997, 350, 1199-1203.
72. Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes, 1994, 43, 369-374.
73. The RINDS Group. Safety profiling of rhIGF-I therapy in patients with NIDDM : a dose-ranging, placebo control trial. Diabetes, 1996, 45, 71A.
74. Quattrin T, Thrakill K, Baker L, Kuntze J, Bajamonde A, Martha P Jr. Recombinant human IGF-I (rhIGF-I) improves metabolic control in adolescents and young adults with IDDM. Horm Res, 1997, 48, 29(Abstract).
75. Keen H. Normoglycaemic re-entry and diabetic complications. Diabetic Medicine, 1984, 1, 85-87.